https://scholars.lib.ntu.edu.tw/handle/123456789/458654
標題: | Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity | 作者: | WEN-FANG CHENG CHIEN-NAN LEE Su Y.-N. Chai C.-Y. Chang M.-C. Polo J.M. Hung C.-F. Wu T.-C. CHANG-YAO HSIEH CHI-AN CHEN |
公開日期: | 2006 | 卷: | 13 | 期: | 9 | 起(迄)頁: | 873-885 | 來源出版物: | Cancer Gene Therapy | 摘要: | Alphavirus vectors have emerged as a promising strategy for the development of cancer vaccines and gene therapy applications. In this study, we used the replication-defective vaccine vector SIN replicon particles from a new packaging cell line (PCL) to develop SIN replicon particles encoding calreticulin (CRT) linked to a model tumor antigen, human papillomavirus type 16 (HPV16) E7 protein. The linkage of CRT to E7 in SIN replicon particles resulted in a significant increase in E7-specific CD8+ T-cell precursors and a strong antitumor effect against E7-expressing tumors in vaccinated mice. SINrep5-CRT/E7 replicon particles enhanced presentation of E7 through the major histocompatibility complex (MHC) class I pathway by infecting dendritic cells (DCs) directly and pulsing DCs with lysates of cells infected by SINrep5-CRT/E7 replicons. Vaccination of immunocompromised (BALB/c nu/nu) mice with SINrep5-CRT/E7 replicon particles also generated significant reduction of lung tumor nodules, suggesting that antiangiogenesis may contribute to the antitumor effect of SINrep5-CRT/E7 replicon particles. Furthermore, SINrep5-CRT/E7 replicon particles generated long-term in vivo tumor protection effects and antigen-specific memory immunities. We concluded that the CRT strategy used in the context of SIN replicon particles facilitated the generation of a highly effective vaccine for cancer prophylaxis and immunotherapy. ? 2006 Nature Publishing Group All rights reserved. |
URI: | 2-s2.0-33747280364 https://scholars.lib.ntu.edu.tw/handle/123456789/458654 |
ISSN: | 0929-1903 | DOI: | 10.1038/sj.cgt.7700956 | SDG/關鍵字: | calreticulin; cancer vaccine; major histocompatibility antigen class 1; protein E7; tumor antigen; virus vector; Alpha virus; angiogenesis; animal cell; animal experiment; antigen specificity; antineoplastic activity; article; cancer immunotherapy; cell lysate; cellular immunity; controlled study; dendritic cell; female; Human papillomavirus type 16; immunological memory; memory cell; nonhuman; priority journal; replicon; Sindbis virus; T lymphocyte activation; tumor immunity; virus particle; Analysis of Variance; Animals; Calreticulin; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gene Therapy; Human papillomavirus 16; Humans; Immunologic Memory; Immunotherapy; Lung Neoplasms; Mice; Mice, Inbred C57BL; Papillomavirus E7 Proteins; Replicon; Sindbis Virus; Alphavirus; Human papillomavirus type 16; Sindbis virus |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。